Simile Valuation Jumps 9,900% to $20B in Series B

Human behavior simulation firm Simile secures $200M Series B at $20B valuation, reporting 5x revenue growth and tens of millions of simulations for Fortune 100 clients.

Woofun AI reports that Simile has closed a $200 million Series B funding round, establishing a post-money valuation of $20 billion. The company, which debuted five months ago after a $100 million Series A, states it has achieved a fivefold increase in revenue. Its technology enables clients to survey tens of thousands to millions of "AI doppelgängers" trained on real human data to predict demographic reactions to products, marketing, or policies.

Fortune 100 companies have utilized Simile's models for tens of millions of simulations. CVS Health deployed 400,000 doppelgängers to analyze medication adherence, while Deloitte, Gallup, and Wealthfront also employ the platform. CEO Joon Sung Park, known for the 2023 "Stanfordville" paper featuring autonomous AI agents, aims to simulate all 8 billion global inhabitants.

However, external observers question whether AI doppelgängers can fully replace real individuals, noting the tool currently functions primarily as a rapid screening mechanism for traditional market research.